Clinical Trial Update: A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating NIO752's effect on tau synthesis in Alzheimer's disease, including autosomal dominant familial forms caused by PSEN1, PSEN2, or APP m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Autosomal Dominant Alzheimer Disease Due to App Mutation
• Autosomal Dominant Alzheimer Disease Due to Psen1 Mutation
• Autosomal Dominant Alzheimer Disease Due to Psen2 Mutation

Drugs mentioned

• NIO752

Snippet

Sponsor: University College, London | Conditions: Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) | Phase 1 | Status: RECRUITING